{"id":"W4402540651","doi":"10.1016/j.annonc.2024.08.2242","title":"ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Eisai; Natera; Seagen; Incyte; BeiGene; Clovis Oncology; Novocure; Exelixis; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Mersana Therapeutics; Karyopharm Therapeutics; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Placebo; Chemotherapy; Adjuvant; Oncology; Radiation therapy; Internal medicine; Cancer; Immunotherapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001868001,0.001926825,0.003366523,0.0006255049,0.0005118569,0.001117304,0.001260099,0.00210425,0.009866416],"category_scores_gemma":[0.001349042,0.0009275958,0.001576799,0.0004627286,0.001450938,0.001259915,0.0004069467,0.003893983,0.001647625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007548558,"about_ca_system_score_gemma":0.001462881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001532906,"about_ca_topic_score_gemma":0.003582567,"domain_scores_codex":[0.9994752,0.0002790771,0.00002451202,0.00008928666,0.00003395597,0.00009794006],"domain_scores_gemma":[0.9994168,0.0001663922,0.00008763311,0.00004328524,0.00003351284,0.0002523259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9654543,0.01008736,0.0002238766,0.0008161233,0.0006263945,0.00002869186,0.00004600101,0.0003179562,0.004437056,0.0001639073,0.0009013305,0.016897],"study_design_scores_gemma":[0.9510553,0.04723594,0.0005372944,0.00001862091,0.0001914247,0.00001474902,0.00001574219,0.0001751002,0.0002578406,0.0000646709,0.0004228062,0.00001065061],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9717007,0.00916821,0.001694678,0.001150134,0.001542772,0.007232168,0.002142536,0.0003668531,0.005001862],"genre_scores_gemma":[0.9717723,0.005974825,0.002665222,0.001955947,0.0006221661,0.006303026,0.001654807,0.00006531135,0.008986245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009866416,"threshold_uncertainty_score":0.03300643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06538704027016648,"score_gpt":0.4011213257799936,"score_spread":0.3357342855098271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}